MCID: UTR033
MIFTS: 45

Uterine Corpus Cancer

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Uterine Corpus Cancer

MalaCards integrated aliases for Uterine Corpus Cancer:

Name: Uterine Corpus Cancer 12 15 17 71
Malignant Uterine Corpus Neoplasm 71
Corpus Uteri Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9460
ICD9CM 34 182
NCIt 49 C3556
SNOMED-CT 67 371972005
ICD10 32 C54 C54.9
UMLS 71 C0153574 C1883486

Summaries for Uterine Corpus Cancer

Disease Ontology : 12 A uterine cancer that is located in the uterine corpus.

MalaCards based summary : Uterine Corpus Cancer, also known as malignant uterine corpus neoplasm, is related to uterine corpus endometrial carcinoma and endometrial serous adenocarcinoma. An important gene associated with Uterine Corpus Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. Affiliated tissues include uterine corpus, breast and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Uterine Corpus Cancer

Diseases related to Uterine Corpus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 395)
# Related Disease Score Top Affiliating Genes
1 uterine corpus endometrial carcinoma 32.0 U2AF1 TP53 SLC25A16 PTEN PPP2R1A POLE
2 endometrial serous adenocarcinoma 32.0 TP53 PTEN PPP2R1A POLE PIK3CA KRAS
3 endometrial cancer 31.7 TP53 S100A6 PTEN PPP2R1A POLE PIK3CA
4 uterine body mixed cancer 31.2 U2AF1 TP53 SLC25A16 PTEN PPP2R1A POLE
5 clear cell adenocarcinoma 30.8 TP53 PIK3CA ARID1A
6 papillary serous adenocarcinoma 30.7 TP53 KRAS BRCA1
7 adenosquamous carcinoma 30.5 TP53 PTEN PIK3CA KRAS EGFR
8 endometrial adenocarcinoma 30.2 TP53 PTEN KRAS ESR1 ERBB2 EGFR
9 cervical cancer 30.0 TP53 PTEN PIK3CA MYC HRAS ESR1
10 adenocarcinoma 30.0 U2AF1 TP53 PTEN POLE PIK3CA MYC
11 bladder cancer 29.8 TP53 PTEN PIK3CA MYC MIR10B KRAS
12 serous cystadenocarcinoma 29.4 TP53 PTEN PPP2R1A POLE PIK3CA MIR10B
13 ovarian cancer 29.0 TP53 PTEN PIK3CA MYC MIR10B KRAS
14 uterine corpus sarcoma 11.6
15 mixed endometrial stromal and smooth muscle tumor 11.3
16 rare head and neck tumor 10.7 TP53 PIK3CA
17 thyroid hurthle cell adenoma 10.7 PTEN PIK3CA
18 glassy cell carcinoma of the cervix 10.7 ESR1 ERBB2
19 breast sarcoma 10.7 TP53 PIK3CA ERBB2
20 gastric papillary adenocarcinoma 10.7 TP53 ERBB2
21 bartholin's gland adenoma 10.7 TP53 ESR1
22 bartholin's gland benign neoplasm 10.7 TP53 ESR1
23 malignant spiradenoma 10.7 TP53 PIK3CA ERBB2
24 vestibular gland benign neoplasm 10.7 TP53 ESR1
25 prostate squamous cell carcinoma 10.7 TP53 HRAS
26 clear cell adenofibroma 10.7 PPP2R1A PIK3CA ARID1A
27 myoepithelial carcinoma 10.7 TP53 PIK3CA HRAS
28 comedo carcinoma 10.6 TP53 ESR1 ERBB2
29 rare adenocarcinoma of the breast 10.6 TP53 PIK3CA KRAS
30 anal carcinoma in situ 10.6 TP53 MYC
31 vulvar intraepithelial neoplasia 10.6 TP53 CTNNB1
32 parameningeal embryonal rhabdomyosarcoma 10.6 TP53 PIK3CA FBXW7
33 frontal lobe neoplasm 10.6 TP53 MYC EGFR
34 breast papillary carcinoma 10.6 PIK3CA ESR1 ERBB2
35 neurofibroma 10.6 TP53 PTEN EGFR
36 signet ring basal cell carcinoma 10.6 KRAS HRAS
37 hyperplastic polyposis syndrome 10.6 TP53 KRAS
38 vulva basal cell carcinoma 10.6 MYC ERBB2
39 familiar ovarian carcinoma 10.6 PIK3CA BRCA1
40 ovarian clear cell adenofibroma 10.6 PTEN PIK3CA KRAS
41 breast squamous cell carcinoma 10.6 HRAS ERBB2
42 anal squamous cell carcinoma 10.6 TP53 PIK3CA FBXW7
43 trachea carcinoma in situ 10.6 KRAS HRAS
44 gallbladder benign neoplasm 10.6 TP53 KRAS HRAS
45 cobblestone retinal degeneration 10.6 KRAS HRAS
46 oncocytic breast carcinoma 10.6 ESR1 ERBB2
47 adenosarcoma 10.6 TP53 ESR1 ERBB2
48 intraductal breast benign neoplasm 10.6 PIK3CA ESR1 ERBB2
49 hemimegalencephaly 10.6 PIK3CA MYC CTNNB1
50 ovarian clear cell adenocarcinoma 10.6 TP53 PIK3CA ARID1A

Graphical network of the top 20 diseases related to Uterine Corpus Cancer:



Diseases related to Uterine Corpus Cancer

Symptoms & Phenotypes for Uterine Corpus Cancer

GenomeRNAi Phenotypes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 57)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.93 HRAS KRAS PIK3CA EGFR
2 Decreased viability GR00055-A-2 10.93 HRAS KRAS PIK3CA EGFR
3 Decreased viability GR00055-A-3 10.93 KRAS
4 Decreased viability GR00106-A-0 10.93 KRAS
5 Decreased viability GR00221-A-1 10.93 ESR1 HRAS KRAS PIK3CA EGFR MYC
6 Decreased viability GR00221-A-2 10.93 BRCA1 ESR1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.93 BRCA1 HRAS MYC
8 Decreased viability GR00221-A-4 10.93 ESR1 PIK3CA EGFR
9 Decreased viability GR00249-S 10.93 MYC
10 Decreased viability GR00301-A 10.93 BRCA1 KRAS
11 Decreased viability GR00381-A-1 10.93 KRAS
12 Decreased viability GR00386-A-1 10.93 ESR1
13 Decreased viability GR00402-S-2 10.93 ESR1 PIK3CA MYC
14 Increased shRNA abundance (Z-score > 2) GR00366-A-1 10.51 POLE
15 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.51 KRAS
16 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.51 EGFR FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.51 FBXW7
18 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.51 POLE
19 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.51 BRCA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-139 10.51 BRCA1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.51 PTEN
22 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.51 PTEN
23 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.51 ERBB2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.51 ARID1A BRCA1 ERBB2 POLE PTEN
25 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.51 ARID1A
26 Increased shRNA abundance (Z-score > 2) GR00366-A-183 10.51 FBXW7
27 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.51 ARID1A
28 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.51 ARID1A
29 Increased shRNA abundance (Z-score > 2) GR00366-A-196 10.51 HRAS
30 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.51 POLE
31 Increased shRNA abundance (Z-score > 2) GR00366-A-204 10.51 BRCA1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.51 ERBB2 POLE
33 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.51 EGFR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-211 10.51 BRCA1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-213 10.51 ARID1A
36 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.51 EGFR PTEN
37 Increased shRNA abundance (Z-score > 2) GR00366-A-22 10.51 KRAS
38 Increased shRNA abundance (Z-score > 2) GR00366-A-28 10.51 HRAS
39 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.51 ERBB2 POLE
40 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.51 PTEN
41 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.51 ARID1A EGFR
42 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.51 FBXW7
43 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.51 ERBB2
44 Increased shRNA abundance (Z-score > 2) GR00366-A-63 10.51 ERBB2 KRAS POLE PTEN
45 Increased shRNA abundance (Z-score > 2) GR00366-A-66 10.51 PTEN
46 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.51 ARID1A
47 Increased shRNA abundance (Z-score > 2) GR00366-A-82 10.51 H2AC18
48 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.51 HRAS
49 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.51 EGFR ERBB2 POLE
50 Increased shRNA abundance (Z-score > 2) GR00366-A-87 10.51 HRAS ERBB2 POLE PTEN

MGI Mouse Phenotypes related to Uterine Corpus Cancer:

45 (show all 26)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.44 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
2 endocrine/exocrine gland MP:0005379 10.44 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
3 growth/size/body region MP:0005378 10.43 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
4 homeostasis/metabolism MP:0005376 10.43 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
5 cellular MP:0005384 10.4 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
6 mortality/aging MP:0010768 10.4 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
7 embryo MP:0005380 10.38 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
8 digestive/alimentary MP:0005381 10.35 BRCA1 CTNNB1 EGFR ERBB2 ESR1 FBXW7
9 integument MP:0010771 10.35 BRCA1 CTNNB1 EGFR ERBB2 ESR1 FBXW7
10 immune system MP:0005387 10.33 ARID1A BRCA1 CTNNB1 EGFR ESR1 FBXW7
11 neoplasm MP:0002006 10.33 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
12 hematopoietic system MP:0005397 10.31 ARID1A BRCA1 CTNNB1 EGFR ESR1 FBXW7
13 craniofacial MP:0005382 10.26 ARID1A CTNNB1 EGFR ERBB2 FBXW7 HRAS
14 nervous system MP:0003631 10.25 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
15 muscle MP:0005369 10.22 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
16 limbs/digits/tail MP:0005371 10.18 BRCA1 CTNNB1 EGFR ERBB2 ESR1 KRAS
17 normal MP:0002873 10.18 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
18 adipose tissue MP:0005375 10.17 BRCA1 EGFR ESR1 MYC PIK3CA PTEN
19 liver/biliary system MP:0005370 10.11 CTNNB1 EGFR ESR1 FBXW7 KRAS MYC
20 no phenotypic analysis MP:0003012 10.06 ARID1A CTNNB1 EGFR ESR1 HRAS KRAS
21 hearing/vestibular/ear MP:0005377 10.05 ARID1A CTNNB1 EGFR KRAS MYC TP53
22 reproductive system MP:0005389 9.93 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1
23 pigmentation MP:0001186 9.87 BRCA1 CTNNB1 EGFR KRAS MYC PTEN
24 renal/urinary system MP:0005367 9.86 BRCA1 CTNNB1 EGFR ESR1 HRAS KRAS
25 respiratory system MP:0005388 9.65 BRCA1 CTNNB1 EGFR ERBB2 ESR1 FBXW7
26 skeleton MP:0005390 9.4 ARID1A BRCA1 CTNNB1 EGFR ERBB2 ESR1

Drugs & Therapeutics for Uterine Corpus Cancer

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 The Effectiveness of a Comprehensive Physical Activity Behavioral Intervention on Underserved Diverse Obese Endometrial Cancer Survivors Completed NCT02575872
2 The Relationship of Racial Genetic Admixture With Endometrial Cancer Outcomes Not yet recruiting NCT01198171

Search NIH Clinical Center for Uterine Corpus Cancer

Genetic Tests for Uterine Corpus Cancer

Anatomical Context for Uterine Corpus Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Corpus Cancer:

19
Uterine Corpus

MalaCards organs/tissues related to Uterine Corpus Cancer:

40
Breast, Lymph Node, Ovary, Uterus, Bone, Myeloid

Publications for Uterine Corpus Cancer

Articles related to Uterine Corpus Cancer:

(show top 50) (show all 136)
# Title Authors PMID Year
1
Major clinical research advances in gynecologic cancer in 2019. 61
32319232 2020
2
Hyaluronic acid gel injection in rectovaginal septum reduced incidence of rectal bleeding in brachytherapy for gynecological malignancies. 61
31879238 2020
3
Clinical and histopathologic analysis of gynecological cancer: a single institute experience over 7 years. 61
32131080 2020
4
Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial. 61
31348579 2019
5
Beyond Obesity: The Rising Incidence and Mortality Rates of Uterine Corpus Cancer. 61
31232669 2019
6
Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. 61
31116674 2019
7
Emerging cancer trends among young adults in the USA: analysis of a population-based cancer registry. 61
30733056 2019
8
Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000-2014. 61
29795414 2018
9
Secondary Breast, Ovarian, and Uterine Cancers After Colorectal Cancer: A Nationwide Population-Based Cohort Study in Korea. 61
30239394 2018
10
Efficacy and safety of nivolumab in patients with uterine cervical cancer, uterine corpus cancer, or soft-tissue sarcoma. 61
32177459 2018
11
Advancing Uterine Cancer Survivorship Among African American Women. 61
30126566 2018
12
The bidirectional association among female hormone-related cancers: breast, ovary, and uterine corpus. 61
29659167 2018
13
Major clinical research advances in gynecologic cancer in 2017. 61
29468855 2018
14
Enhancement of Uterine Cancer Development after Oocyte Depletion by Juvenile Exposure 
to Gamma Radiation in Rats: - A Comparative Study on Sensitivity of Damage to 
Female Reproductive Organs by Radiation 
between Juvenile and Adulthood Using a Rat Model. 61
32231939 2017
15
Survival of Cancer Patients in Northeast China: Analysis of Sampled Cancers from Population-Based Cancer Registries. 61
28161932 2017
16
Reply to "Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women". 61
28805626 2017
17
Need for an up to date and comprehensive risk factor analysis to determine the lifetime risk of uterine corpus cancer in Taiwan women. 61
28805629 2017
18
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition. 61
28382802 2017
19
Gemella morbillorum bacteremia following total laparoscopic hysterectomy for uterine corpus cancer. 61
30254882 2017
20
Incidence and lifetime risk of uterine corpus cancer in Taiwanese women from 1991 to 2010. 61
28254229 2017
21
Laparoscopic Repair of Vaginal Evisceration after Abdominal Hysterectomy for Uterine Corpus Cancer: A Case Report and Literature Review. 61
28502966 2017
22
Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement. 61
27894165 2017
23
High lncRNA H19 expression as prognostic indicator: data mining in female cancers and polling analysis in non-female cancers. 61
27926484 2017
24
A prediction model of survival for patients with bone metastasis from uterine corpus cancer. 61
27655906 2016
25
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. 61
27367496 2016
26
Hysterectomy for Uterine Cancer in the Elderly: A Comparison Between Laparoscopic and Robot-Assisted Techniques. 61
27648646 2016
27
Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? 61
27261326 2016
28
Genitofemoral neuropathy after pelvic lymphadenectomy in patients with uterine corpus cancer. 61
25486104 2015
29
Trends in gynecologic cancer mortality in East Asian regions. 61
25045429 2014
30
Comorbidity is an independent prognostic factor in women with uterine corpus cancer: a nationwide cohort study. 61
24443826 2014
31
A prospective study of gynecological cancer risk in relation to adiposity factors: cumulative incidence and association with plasma adipokine levels. 61
25115836 2014
32
Concurrent Malignant Solitary Fibrous Tumor Arising from the Omentum and Grade 3 Endometrial Endometrioid Adenocarcinoma of the Uterus with p53 Immunoreactivity. 61
25114818 2014
33
Grave outcome of granulocyte colony-stimulating factor-producing endometrial cancer: a case report and literature review. 61
23279043 2013
34
Treg cells in different forms of uterine cancer. 61
23178746 2013
35
State-level uterine corpus cancer incidence rates corrected for hysterectomy prevalence, 2004 to 2008. 61
23125334 2013
36
Synchronous primary corpus and ovarian cancer: High incidence of endometriosis and thrombosis. 61
22970036 2012
37
[Epidemiology of uterine corpus cancer in some cancer registering areas of China from 2003 - 2007]. 61
22932112 2012
38
[Uterine corpus cancer: dynamics of morbidity, mortality and survival]. 61
22888648 2012
39
Endometrioid adenocarcinoma with high-grade transformation with serous and choriocarcinomatous differentiation - a case report. 61
22211141 2012
40
[Diaphragmatic metastasis from uterine corpus cancer]. 61
21842675 2011
41
Efficacy of para-aortic lymphadenectomy in early-stage endometrioid uterine corpus cancer. 61
21136177 2011
42
Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer. 61
21705925 2011
43
Comparative performance of the 2009 International Federation of Gynecology and Obstetrics' staging system for uterine corpus cancer. 61
21508766 2011
44
The value of MR imaging when the site of uterine cancer origin is uncertain. 61
21212371 2011
45
A retrospective analysis of postoperative complications with or without para-aortic lymphadenectomy in endometrial cancer. 61
21270621 2011
46
Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. 61
20966700 2010
47
Current status in the management of uterine corpus cancer in Korea. 61
20922137 2010
48
Evaluation of FDG-PET for detecting lymph node metastasis in uterine corpus cancer. 61
20944170 2010
49
Cervical, uterine corpus, and ovarian cancer mortality in Greece during 1980 to 2005: a trend analysis. 61
20686368 2010
50
Metabolic syndrome and endometrial carcinoma. 61
20219764 2010

Variations for Uterine Corpus Cancer

Copy number variations for Uterine Corpus Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 162862 22 22706138 22714284 Decreasing copy number GSTT1 Corpus uteri cancer

Expression for Uterine Corpus Cancer

Search GEO for disease gene expression data for Uterine Corpus Cancer.

Pathways for Uterine Corpus Cancer

Pathways related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 124)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.28 TP53 PTEN PPP2R1A PIK3CA MYC KRAS
2
Show member pathways
14.13 TP53 PTEN PPP2R1A PIK3CA MYC KRAS
3
Show member pathways
13.92 TP53 PTEN PPP2R1A MYC KRAS HRAS
4
Show member pathways
13.9 U2AF1 TP53 PTEN PPP2R1A MYC H2AC18
5
Show member pathways
13.81 PPP2R1A PIK3CA MYC KRAS HRAS FBXW7
6
Show member pathways
13.8 TP53 PPP2R1A MYC KRAS HRAS ESR1
7
Show member pathways
13.64 TP53 PPP2R1A PIK3CA MYC KRAS HRAS
8
Show member pathways
13.6 PPP2R1A PIK3CA KRAS HRAS H2AC18 ERBB2
9
Show member pathways
13.55 TP53 PTEN PPP2R1A PIK3CA KRAS HRAS
10
Show member pathways
13.46 TP53 PPP2R1A PIK3CA MYC KRAS HRAS
11
Show member pathways
13.37 PPP2R1A KRAS HRAS ESR1 ERBB2 EGFR
12
Show member pathways
13.31 TP53 PTEN MYC KRAS HRAS ERBB2
13
Show member pathways
13.2 TP53 PTEN PPP2R1A PIK3CA ERBB2 EGFR
14
Show member pathways
13.17 TP53 PTEN PIK3CA KRAS HRAS EGFR
15
Show member pathways
13.17 TP53 PPP2R1A PIK3CA MYC KRAS HRAS
16
Show member pathways
13.05 TP53 PIK3CA MYC KRAS HRAS EGFR
17
Show member pathways
13.01 PTEN PIK3CA KRAS HRAS ERBB2 EGFR
18
Show member pathways
13.01 TP53 PTEN PPP2R1A PIK3CA MYC KRAS
19
Show member pathways
13 PTEN PIK3CA KRAS HRAS ERBB2 EGFR
20
Show member pathways
13 TP53 PTEN PIK3CA MYC KRAS HRAS
21
Show member pathways
12.96 PTEN PIK3CA KRAS HRAS ERBB2 EGFR
22
Show member pathways
12.94 TP53 PTEN MYC H2AC18 ESR1 BRCA1
23
Show member pathways
12.88 TP53 PTEN PPP2R1A PIK3CA KRAS HRAS
24 12.88 TP53 PTEN PIK3CA MYC KRAS HRAS
25
Show member pathways
12.87 PTEN PIK3CA MYC KRAS HRAS
26 12.87 TP53 MYC KRAS HRAS ERBB2 EGFR
27
Show member pathways
12.87 TP53 PTEN PIK3CA KRAS HRAS ESR1
28
Show member pathways
12.83 PIK3CA KRAS HRAS EGFR CTNNB1
29
Show member pathways
12.81 TP53 POLE MYC FBXW7 ESR1 BRCA1
30
Show member pathways
12.8 TP53 PIK3CA MYC KRAS HRAS
31
Show member pathways
12.77 PIK3CA KRAS HRAS ESR1 EGFR
32
Show member pathways
12.76 TP53 PPP2R1A KRAS HRAS EGFR
33
Show member pathways
12.76 TP53 PTEN PIK3CA MYC KRAS HRAS
34
Show member pathways
12.76 TP53 PTEN PIK3CA KRAS HRAS ESR1
35
Show member pathways
12.74 PIK3CA KRAS HRAS EGFR CTNNB1
36
Show member pathways
12.73 TP53 PIK3CA MYC KRAS HRAS ERBB2
37
Show member pathways
12.7 PTEN PIK3CA KRAS HRAS EGFR
38
Show member pathways
12.66 TP53 PTEN PIK3CA KRAS HRAS ERBB2
39
Show member pathways
12.64 PTEN PIK3CA MYC KRAS HRAS ESR1
40
Show member pathways
12.63 TP53 PTEN PIK3CA MYC KRAS HRAS
41
Show member pathways
12.61 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
42
Show member pathways
12.56 PIK3CA MYC KRAS HRAS EGFR
43
Show member pathways
12.53 PIK3CA KRAS HRAS ESR1 CTNNB1 BRCA1
44
Show member pathways
12.52 PTEN PIK3CA MYC KRAS HRAS
45
Show member pathways
12.51 PIK3CA KRAS HRAS ERBB2 EGFR CTNNB1
46
Show member pathways
12.51 TP53 PTEN PIK3CA MYC HRAS
47 12.51 TP53 PTEN PIK3CA MYC MIR10B KRAS
48
Show member pathways
12.49 PIK3CA KRAS HRAS EGFR
49 12.48 U2AF1 TP53 PIK3CA EGFR
50 12.48 TP53 PTEN PIK3CA MYC KRAS HRAS

GO Terms for Uterine Corpus Cancer

Cellular components related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 10 U2AF1 TP53 PTEN POLE MYC HRAS
2 protein-containing complex GO:0032991 9.63 TP53 MYC ESR1 EGFR CTNNB1 BRCA1
3 nucleus GO:0005634 9.53 U2AF1 TP53 S100A6 PTEN PPP2R1A POLE
4 perinuclear region of cytoplasm GO:0048471 9.43 S100A6 HRAS FBXW7 ERBB2 EGFR CTNNB1

Biological processes related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 TP53 MYC HRAS ESR1 EGFR CTNNB1
2 positive regulation of transcription, DNA-templated GO:0045893 10 TP53 MYC ESR1 EGFR CTNNB1 BRCA1
3 regulation of transcription by RNA polymerase II GO:0006357 9.97 TP53 MYC ESR1 ERBB2 EGFR CTNNB1
4 heart development GO:0007507 9.96 TP53 PTEN ERBB2 CTNNB1
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.93 PTEN HRAS FBXW7 EGFR
6 regulation of cell proliferation GO:0042127 9.92 TP53 EGFR CTNNB1 BRCA1
7 protein deubiquitination GO:0016579 9.91 TP53 PTEN MYC ESR1 BRCA1
8 positive regulation of protein phosphorylation GO:0001934 9.9 KRAS HRAS ERBB2 EGFR
9 MAPK cascade GO:0000165 9.89 MYC KRAS HRAS ERBB2 EGFR
10 positive regulation of protein kinase B signaling GO:0051897 9.88 PIK3CA ESR1 ERBB2 EGFR
11 positive regulation of cell proliferation GO:0008284 9.87 PTEN MYC KRAS HRAS ERBB2 EGFR
12 Ras protein signal transduction GO:0007265 9.81 TP53 KRAS HRAS
13 cellular response to growth factor stimulus GO:0071363 9.81 ERBB2 EGFR CTNNB1
14 cellular response to drug GO:0035690 9.79 TP53 MYC EGFR
15 liver development GO:0001889 9.78 PIK3CA KRAS HRAS EGFR
16 cellular response to epidermal growth factor stimulus GO:0071364 9.74 MYC ERBB2 EGFR
17 phosphatidylinositol 3-kinase signaling GO:0014065 9.73 PTEN PIK3CA ERBB2
18 positive regulation of epithelial cell proliferation GO:0050679 9.73 MYC HRAS ERBB2 EGFR
19 negative regulation of gene expression GO:0010629 9.73 TP53 MYC HRAS FBXW7 ESR1 CTNNB1
20 androgen receptor signaling pathway GO:0030521 9.72 CTNNB1 BRCA1 ARID1A
21 ERBB2 signaling pathway GO:0038128 9.71 PIK3CA ERBB2 EGFR
22 positive regulation of MAP kinase activity GO:0043406 9.71 KRAS HRAS ERBB2 EGFR
23 vasculature development GO:0001944 9.7 PIK3CA FBXW7 CTNNB1
24 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.65 TP53 EGFR
25 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.65 TP53 ESR1
26 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.64 TP53 ESR1
27 response to isolation stress GO:0035900 9.61 KRAS HRAS
28 negative regulation of ERBB signaling pathway GO:1901185 9.59 ERBB2 EGFR
29 cellular response to indole-3-methanol GO:0071681 9.58 CTNNB1 BRCA1
30 positive regulation of fibroblast proliferation GO:0048146 9.46 S100A6 MYC ESR1 EGFR
31 response to estradiol GO:0032355 9.35 PTEN MYC ESR1 EGFR CTNNB1
32 positive regulation of gene expression GO:0010628 9.23 TP53 PTEN MYC KRAS HRAS ERBB2

Molecular functions related to Uterine Corpus Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.77 TP53 PTEN ESR1 EGFR CTNNB1
2 chromatin binding GO:0003682 9.72 TP53 POLE ESR1 EGFR CTNNB1
3 repressing transcription factor binding GO:0070491 9.33 MYC ESR1 CTNNB1
4 nitric-oxide synthase regulator activity GO:0030235 9.26 ESR1 EGFR
5 protein phosphatase binding GO:0019903 9.26 TP53 ERBB2 EGFR CTNNB1
6 enzyme binding GO:0019899 9.1 TP53 PTEN ESR1 EGFR CTNNB1 BRCA1

Sources for Uterine Corpus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....